Drug Hunter

What Drug Hunter does

Drug Hunter is a Boston-based B2B subscription knowledge platform founded in 2018 that serves drug discovery scientists working in biotech and pharmaceutical R&D organizations. The company aggregates and curates drug discovery knowledge from thousands of sources, including scientific journals, conferences, patents, databases, and industry news, and presents this content through a searchable cloud-based platform accessible via web, iOS, and Android applications. Core products include Molecule Search (a unified structure search tool launched in April 2026 spanning FDA-approved drugs, clinical compounds, and indexed molecules with biological context), Patent Search, educational courses in medicinal chemistry, Flash Talks from industry conferences, and a library of reference resources and cheat sheets.

The company operates on a subscription membership model, serving both individual researchers and organizational accounts at biotech and pharma companies worldwide, with more than 200 organizations and 15,000+ mailing list subscribers using the platform. Drug Hunter's value proposition centers on saving researchers days or weeks of reading each month by consolidating fragmented drug discovery knowledge into expert-curated content and structured search tools. The platform differentiates through deep domain specialization, an editorial team of experienced medicinal chemists, and content authority built over eight years of operation. In September 2025, Drug Hunter secured a $6,043,381 seed round led by Teamworthy Ventures to fund platform expansion, scientific coverage growth, analytical tool improvements, and mobile app development. The company maintains 11-50 employees and operates as a privately held Delaware corporation headquartered in the United States.

Name

Drug Hunter

Legal name

Drug Hunter Inc.

Website

https://drughunter.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Drug Hunter is a Boston-based B2B subscription platform, founded in 2018, that aggregates and curates drug discovery knowledge from thousands of sources into searchable tools and expert content for biotech and pharma R&D scientists at 200+ organizations worldwide.

Ownership category

akta.pro rank

Product category

Drug Discovery Intelligence Platform

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Drug discovery intelligence
• Medicinal chemistry resources
• Molecule search platform
• Pharma research database
• Drug development knowledge

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Subscription Membership: Drug Hunter operates on a membership/subscription model where researchers and organizations pay for access to the platform's searchable drug discovery knowledge, including case studies, patent search, structure search, and databases.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Drug Hunter is a B2B subscription knowledge platform for drug discovery scientists that aggregates and curates case studies, patent highlights, scientific reviews, conference literature, structure search, and drug databases from thousands of sources into a single searchable cloud platform. The platform is delivered through web, iOS, and Android channels and is used by biotech and pharmaceutical R&D organizations to support molecule research, patent analysis, and ongoing medicinal chemistry education.

Product overview

Drug Hunter is a drug discovery knowledge platform that consolidates industry lessons from thousands of sources into a searchable database. The platform comprises Molecule Search (a unified structure search across FDA-approved drugs, clinical compounds, and Drug Hunter indexed molecules), Patent Search, Course (educational medicinal chemistry modules), Flash Talks (conference presentations), and Resources (cheat sheets and guides). The platform is designed to help biotech and pharma researchers access drug discovery case studies, patent highlights, scientific reviews, and conference literature to stay current in the field.

Differentiator

Problem solved

Functional benefit

Products and services

• Molecule Search A unified structure search platform that enables drug discovery researchers to run parallel searches across FDA-Approved Drugs, Modern Clinical Compounds, Recent Disclosures, and Drug Hunter indexed molecules simultaneously. It pairs chemical matter with biological context including indexed targets, mechanisms of action, 3D structure information, and therapeutic areas, and is available to all Drug Hunter members.
• Patent Search A searchable database of patents related to drug discovery that allows researchers to explore patent landscapes and drug discovery strategies within the Drug Hunter platform.
• Drug Hunter Course Educational medicinal chemistry courses covering topics such as Protein Structure & Target Pharmacology, Property-Based Design, and Medicinal Chemistry Principles: Potency, designed to help drug discovery scientists stay current in the field.
• Flash Talks A series of presentations from drug discovery conferences, providing insights into recent industry developments and scientific discoveries for drug discovery researchers.

Quantifiable outcome

• Saves researchers days, if not weeks of reading each month

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• BenchSci: BenchSci is an AI-powered research platform that helps life sciences scientists find antibodies, reagents, and relevant published figures from the literature. It targets the same biotech and pharma research audience with a content-plus-software model and similar PLG distribution.
• Endpoints News: Endpoints News is a subscription-based biopharma news and intelligence outlet covering drug development, deals, and clinical readouts. It shares Drug Hunter's subscription model and focus on pharma/biotech decision-makers, though with more emphasis on news than technical content.
• BioSpace: BioSpace is a B2B platform serving biopharma professionals with news, job listings, and industry intelligence. It shares Drug Hunter's horizontal life sciences audience and advertising/subscription monetization model, making it a comparable business even if content focus differs.

Broad incumbents

• STAT News: STAT is a leading subscription-supported life sciences news brand covering pharma, biotech, and health policy. It overlaps with Drug Hunter in monetizing deep biopharma content to professional subscribers, but operates at much larger scale and broader scope.
• CAS (Chemical Abstracts Service): CAS operates SciFinder and related chemistry databases used by drug discovery researchers worldwide. It is the dominant incumbent in chemistry literature and substance search, comparable to Drug Hunter's Molecule Search and patent search functionality but vastly larger and broader in scope.
• Citeline (Pharma Intelligence): Citeline offers subscription intelligence products (e.g., Trialtrove, Pharmaprojects) covering the drug development pipeline, clinical trials, and deals. It serves the same pharma R&D audience as Drug Hunter with paid intelligence subscriptions, but at much greater breadth and enterprise scale.
• Informa Pharma Intelligence: Informa Pharma Intelligence provides subscription databases, pipeline trackers, and analysis for the biopharma industry. It is comparable to Drug Hunter as a subscription intelligence vendor serving drug development professionals, though with substantially deeper enterprise offerings.
• Reaxys: Reaxys is an Elsevier-operated chemistry and drug discovery database widely used by medicinal chemists for compound, reaction, and patent searching. It directly competes with Drug Hunter's structure and patent search capabilities as an established incumbent tool.

Emerging players

• Elicit: Elicit is an AI research assistant that helps scientists find, summarize, and extract data from academic literature. It overlaps with Drug Hunter in serving scientific researchers with knowledge tools, but uses AI agents rather than human curation, posing a competitive threat.

Others

• The Lens: The Lens is a free and subscription patent and scholarly search platform with deep patent landscape analytics. It is adjacent to Drug Hunter's Patent Search feature and serves a partly overlapping researcher audience, functioning more as an enabling data source than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/drughunter_com
• YouTubeyoutube.com/@drughunter
• Facebookfacebook.com/drughunterofficial
• LinkedInlinkedin.com/company/drughunter
• Instagraminstagram.com/drughunterofficial

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drug Hunter